HERON THERAPEUTICS, INC. /DE/ — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Heron reported Q2 2026 net revenue of $37.7M (up 9% QoQ), with ZYNRELEF growing 35% YoY and APONVIE growing 74% YoY. The company amended its credit facility with Hercules Capital, reducing outstanding principal by $13.5M at execution plus a potential $4M reduction by September 15, 2026. Critically, Heron withdrew full-year 2026 financial guidance due to three factors: a June 2026 U.S. District Court decision threatening CINVANTI (its largest product) with potential generic entry; a pause on planned sales force expansion and spending tightening in response; and active consideration of strategic alternatives with no timetable set.
Why this rating
Guidance withdrawal + patent loss + strategic review + debt restructuring signal material distress. Relative to $235M market cap, the $42.7M cash balance and debt restructuring are substantial. CINVANTI patent ruling threatens largest revenue driver; strategic alternatives language indicates possible dilutive transaction or restructuring.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.